

Akari Therapeutics, PLC  
75/76 Wimpole Street  
London W1G 9RT  
United Kingdom

November 7, 2022

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: Akari Therapeutics, PLC**  
**Registration Statement on Form F-1**  
**File No. 333-267840**

VIA EDGAR

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Akari Therapeutics, PLC (the “**Registrant**”) hereby respectfully requests that the effectiveness of the Registration Statement on Form F-1 (File No. 333-267840) of the Registrant (the “**Registration Statement**”) be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on November 8, 2022 or as soon thereafter as may be practicable.

The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by telephone call to our counsel, McDermott Will & Emery LLP, by calling Richard Bass at (212) 547-5476. The Company hereby authorizes Mr. Bass to orally modify or withdraw this request for acceleration.

---

Very truly yours,

AKARI THERAPEUTICS, PLC

By: /s/ Torsten Hombeck

Name: Torsten Hombeck

Title: Chief Financial Officer

---